Forbes  2 hrs ago  Comment 
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Facebook Inc (NASD: FB), where a total volume of 342,785 contracts has been traded thus far today, a contract volume which is...
Motley Fool  Oct 26  Comment 
Is the recent setback for fasinumab a mountain or a molehill for Regeneron?
Forbes  Oct 21  Comment 
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Altria Group Inc (NYSE: MO), where a total volume of 46,636 contracts has been traded thus far today, a contract volume which is...
Benzinga  Oct 17  Comment 
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Teva Pharmaceuticals Ltd (ADR) (NYSE: TEVA) came under selling pressure after the FDA placed the second stage study on chronic low back pain on hold. The companies are involved in...
Benzinga  Oct 13  Comment 
Following a strategic collaboration, option and license agreement Ocular Therapeutix Inc (NASDAQ: OCUL) announced with Regeneron Pharmaceuticals Inc (NASDAQ: REGN), BTIG said the deal provides external validation for the former's platform...
Motley Fool  Oct 13  Comment 
Roche is much bigger, but is Regeneron the better investing choice between these two biotechs?
Motley Fool  Oct 10  Comment 
Praluent has been disappointing, but the pharma might have another big winner on the way with Dupixent.
Motley Fool  Oct 8  Comment 
Big-cap biotechs Gilead Sciences, Celgene, and Regeneron have lost ground in 2016, but each has catalysts coming that could drive future revenue and profit growth.
Benzinga  Oct 3  Comment 
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the Phase 2 CAPELLA trial of Eylea co-formulated with an anti-PDGFR-beta antibody, runicumab, did not meet the primary endpoint. Baird’s Brian P. Skorney maintained a Neutral rating...
newratings.com  Oct 3  Comment 
MARTINSRIED (dpa-AFX) - Shares of Depomed Inc. (DEPO) touched a new 52-week high on Friday, thanks to the patent infringement suit related to NUCYNTA franchise going in favor of the company. The NUCYNTA franchise includes: NUCYNTA ER extended...


Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki